Engineered FGF21 Fusion Protein Clears Damaged Mitochondria and Aids Spinal Cord Repair
A long-acting FGF21 fusion protein activates mitophagy in injured neurons, restoring mitochondrial health and promoting recovery after spinal cord injury.
Summary
Researchers engineered a modified version of fibroblast growth factor 21 (FGF21) called SFGF21, designed for greater stability and targeting. In mice with spinal cord injury, SFGF21 enhanced communication between mitochondria and lysosomes, triggering a cellular cleanup process called mitophagy that removes damaged mitochondria. This reduced oxidative stress and lipid peroxidation in injured neurons. Experiments blocking key proteins FGFR1 and BNIP3 confirmed both are essential to this protective effect. The findings suggest that engineering proteins to fine-tune organelle interactions could offer a new strategy for treating spinal cord injury and potentially other conditions involving mitochondrial damage in neurons.
Detailed Summary
Spinal cord injury (SCI) triggers a cascade of secondary damage long after the initial trauma, and mitochondrial dysfunction sits at the heart of this destructive process. Injured neurons accumulate dysfunctional mitochondria that generate excessive oxidative stress, accelerating cell death and impairing recovery. Despite this well-established mechanism, therapeutic strategies that restore mitochondrial quality control in the injured spinal cord have remained elusive.
This study introduces SFGF21, an engineered fusion protein derived from fibroblast growth factor 21 (FGF21). The researchers incorporated a specialized linker peptide into the FGF21 structure to improve molecular targeting and resistance to oxidative degradation — two major barriers that limit the therapeutic usefulness of native FGF21 in injury contexts.
In a mouse model of SCI, sustained SFGF21 delivery produced striking results. The protein potentiated dynamic crosstalk between mitochondria and lysosomes, activating the BNIP3/BNIP3L mitophagy pathway. This pathway acts as a cellular recycling system, tagging and clearing dysfunctional mitochondria before they cause further damage. The result was restored mitochondrial homeostasis, suppressed lipid peroxidation, and markedly reduced oxidative stress in injured neurons.
Loss-of-function experiments provided mechanistic clarity: blocking either FGFR1 (the receptor for FGF21) or BNIP3 (a key mitophagy mediator) abolished the neuroprotective benefits of SFGF21, confirming both are required links in the therapeutic chain.
For longevity and healthspan science, these findings are broadly significant. Mitochondrial dysfunction and impaired mitophagy are central hallmarks of aging across many tissue types, not just the injured spinal cord. A protein-engineering approach that reactivates mitophagy via organelle crosstalk could have implications for neurodegenerative diseases, age-related muscle decline, and other conditions driven by accumulating mitochondrial damage. The study opens a compelling avenue for mitochondria-targeted protein therapeutics.
Key Findings
- SFGF21, an engineered FGF21 fusion protein, activated mitophagy and cleared dysfunctional mitochondria in injured spinal cord neurons.
- The protein enhanced mitochondria-lysosome crosstalk, triggering the BNIP3/BNIP3L mitophagy pathway in mouse SCI models.
- Treatment suppressed lipid peroxidation and oxidative stress in injured neurons, key drivers of secondary spinal cord damage.
- Both FGFR1 and BNIP3 are required for SFGF21's neuroprotective effects, confirmed by loss-of-function experiments.
- The approach establishes organelle crosstalk modulation as a therapeutic strategy applicable beyond SCI to aging-related mitochondrial dysfunction.
Methodology
The study used a mouse model of spinal cord injury to test sustained delivery of SFGF21. Mechanistic validation relied on loss-of-function experiments selectively blocking FGFR1 and BNIP3 to confirm their necessity in the observed mitophagy and neuroprotection. The protein itself was engineered with a linker peptide to improve targeting and oxidative stability.
Study Limitations
This summary is based on the abstract only, as the full paper was not accessible. All findings are from a mouse model of SCI, and translation to human spinal cord injury or aging conditions remains unproven. Long-term safety, dosing optimization, and delivery route in larger organisms are not addressed in the available information.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: